Based on the patient’s age at diagnosis, tumor stage and MYCN amplification, NB cases are classified into a low-, intermediate-, or high-risk group following the International Neuroblastoma Risk Group (INRG) (Cohn et al., 2009). This evidence concerns the gene MYCN and neuroblastoma.